SpyGlass Pharma reports 4-year trial data for BIM-IOL glaucoma implant, 23-patient study
SpyGlass Pharma announced interim 4-year results from its first-in-human trial of the Bimatoprost Drug Pad-IOL System, a cataract-surgery implant designed to lower eye pressure for glaucoma or ocular hypertension patients. The company reported a 37% mean reduction in intraocular pressure and no product-related adverse events among 21 evaluable patients, though the study is small and the product remains in clinical development with no approval yet.
Key points
- Mean intraocular pressure fell 37%, from 25.1 to 15.9 mmHg, across all three dose groups at 4 years
- 86% of evaluable patients (18 of 21) remained off all topical IOP-lowering drops
- No product-related adverse events were reported; the trial began with 23 patients, and 21 were evaluable at 48 months
- Company plans to work with the FDA on a 505(b)(2) New Drug Application; long-term follow-up continues through 2029
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.